| Literature DB >> 29348365 |
Joshua D Cohen1,2,3,4,5, Lu Li6, Yuxuan Wang1,2,3,4, Christopher Thoburn3, Bahman Afsari7, Ludmila Danilova7, Christopher Douville1,2,3,4, Ammar A Javed8, Fay Wong1,3,4, Austin Mattox1,2,3,4, Ralph H Hruban3,4,9, Christopher L Wolfgang8, Michael G Goggins3,4,9,10,11, Marco Dal Molin4, Tian-Li Wang3,9, Richard Roden3,9, Alison P Klein3,4,12, Janine Ptak1,2,3,4, Lisa Dobbyn1,3,4, Joy Schaefer1,3,4, Natalie Silliman1,2,3,4, Maria Popoli1,3,4, Joshua T Vogelstein13, James D Browne14, Robert E Schoen15,16, Randall E Brand15, Jeanne Tie17,18,19,20, Peter Gibbs17,18,19,20, Hui-Li Wong17, Aaron S Mansfield21, Jin Jen22, Samir M Hanash23, Massimo Falconi24, Peter J Allen25, Shibin Zhou1,3,4, Chetan Bettegowda1,3,4, Luis A Diaz1,3,4, Cristian Tomasetti26,6,7, Kenneth W Kinzler27,3,4, Bert Vogelstein27,2,3,4, Anne Marie Lennon26,4,8,10,11, Nickolas Papadopoulos27,3,4.
Abstract
Earlier detection is key to reducing cancer deaths. Here, we describe a blood test that can detect eight common cancer types through assessment of the levels of circulating proteins and mutations in cell-free DNA. We applied this test, called CancerSEEK, to 1005 patients with nonmetastatic, clinically detected cancers of the ovary, liver, stomach, pancreas, esophagus, colorectum, lung, or breast. CancerSEEK tests were positive in a median of 70% of the eight cancer types. The sensitivities ranged from 69 to 98% for the detection of five cancer types (ovary, liver, stomach, pancreas, and esophagus) for which there are no screening tests available for average-risk individuals. The specificity of CancerSEEK was greater than 99%: only 7 of 812 healthy controls scored positive. In addition, CancerSEEK localized the cancer to a small number of anatomic sites in a median of 83% of the patients.Entities:
Mesh：
Substances：
Year: 2018 PMID： 29348365 PMCID： PMC6080308 DOI： 10.1126/science.aar3247
Source DB: PubMed Journal: Science ISSN： 0036-8075 Impact factor: 47.728